T Cell Sciences Inc. and ArQule Inc. have begun a collaborationaimed at discovering small molecules that can suppress or activate Tcells, with a goal of finding potential drugs for a variety of diseases.
Compounds will be identified from ArQule's non-peptidic smallmolecule arrays using T Cell Sciences' screens and functional assays.ArQule, of Medford, Mass., and T Cell Sciences, of Needham,Mass., will jointly own rights to resulting compounds.
Alan Tuck, president and CEO of T Cell Sciences, said thecollaborative effort is an example of a way small biotechnologycompanies can create value. Combining the companies' technologiespresents some intriguing possibilities, he said.
"The ArQule agreement is an important step in the emergence of newcreative, commercial relationships, and it builds upon promisingrecent work between the two companies," Tuck said.
No money is changing hands in the deal, Tuck said. Rather, eachcompany is contributing skills.
"This agreement is another example of ArQule's program to leverageits combinatorial chemistry technology through collaborations withoutstanding biology-based companies such as T Cell," said EricGordon, president and CEO of ArQule.
ArQule uses combinatorial chemistry and information technologies todiscovery and optimize molecules. Its technologies enable theaccelerated parallel production of lots of well-characterized, puresmall molecules based on structural information about a target. T CellSciences uses complement inhibition and T cell receptor technologyto develop products for diseases of inflammation and autoimmunity._ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.